secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZEVRA THERAPEUTICS, INC. (ZVRA)
CIK:        0001434647
Form:       8-K
Filed at:   2023-12-27T23:59:59+00:00
Accession:  0001437749-23-035343
Event type: regulatory
Sentiment:  neutral
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zevra resubmits NDA for arimoclomol (NPC) to FDA on Dec 22, 2023
----------------------------------------------------------------

- FDA acknowledgment letter and PDUFA date expected within 30 days.
- Resubmission classified as Class II; review targeted within six months.
- Additional data includes non-clinical studies, natural history, real-world data, and 4-year open-label extension results.
- Open-label extension data suggests arimoclomol reduces long-term NPC progression.
- Arimoclomol evaluated in 21 studies across 600+ subjects.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434647/000143774923035343/0001437749-23-035343-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434647/000143774923035343/zvra20231226_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-035343

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer